Programmes
Selected Programmes
Active programmes and platforms being advanced toward clinical translation and strategic collaboration
We focus on high-impact therapeutic challenges where conventional development approaches are insufficient
Each programme applies predictive modelling, formulation engineering, and translational strategy to create clinically viable and manufacturable assets
From concept to clinic — engineered, not assumed
Drug development rarely fails due to biology—it fails at the interface between molecule, delivery, and human exposure
Our programmes are designed to address these exact failure points—by integrating modelling, formulation, and execution from the outset.
Active Programmes & Platforms
Familial HLH: Precision Cytotoxic Delivery
Oncology / Rare Disease
The Problem
Our Approach
Familial Hemophagocytic Lymphohistiocytosis (HLH) is a severe hyperinflammatory condition requiring potent cytotoxic therapy. Existing treatments are constrained by systemic toxicity, poor targeting, and narrow therapeutic windows
We are developing targeted delivery strategies for cytotoxic agents, including:
- Antibody-Drug Conjugates (ADCs)
- Tumour-activated prodrugs
- Repurposing of epipodophyllotoxins and related agents
Why It Matters
Collaboration Opportunity
- Reduces off-target exposure and systemic toxicity
- Enables controlled, site-specific activation
- Expands the therapeutic window of established cytotoxic agents
We invite partners to co-develop targeted cytotoxic delivery systems for HLH and related indications
Advanced Delivery & Translational Platforms
Cross-Indication
The Opportunity
Our Approach
Across therapeutic areas, clinical failure is frequently driven by delivery constraints rather than intrinsic efficacy
We develop integrated systems combining nanotechnology and targeted delivery, predictive biopharmaceutics via SynapTx™, formulation-driven optimisation, and CMC-aligned development strategies.
Why It Matters
Collaboration Opportunity
- Bridges the gap between molecular potential and clinical exposure
- Enables scalable, regulatory-ready solutions
- De-risks development early
We collaborate on molecules, biological questions, and new technologies to build clinically translatable solutions.
Nitric Oxide Platform: Engineered Antimicrobial Systems
Infectious Disease
The Problem
Our Approach
Nitric oxide is a powerful endogenous antimicrobial agent, but itstherapeutic use is limited by extremely short half-life, high reactivity, and lack of controlled, localised delivery.
We are developing systems that enable controlled in situ nitric oxide generation, localised delivery at the site of action, and combination strategies with complementary reactive species.
Why It Matters
Collaboration Opportunity
- Broad-spectrum antimicrobial activity
- Reduced likelihood of resistance
- Applicability across respiratory, wound, and ENT indications
Open to co-development partnerships in infectious disease and localised therapeutic applications
The Problem
Our Approach
Cannabinoids show strong therapeutic potential but are constrained by poor solubility, variable bioavailability, and unpredictable pharmacokinetics
We are developing nano-enabled delivery systems designed to improve solubility and stability, enhance systemic exposure, and deliver reproducible pharmacokinetic profiles.
Why It Matters
Collaboration Opportunity
- Enables clinical translation of cannabinoid-based therapies
- Supports regulatory-aligned development
- Expands therapeutic applicability
Seeking partners to co-develop clinically translatable cannabinoid formulations
Extracellular Matrix (ECM) Modulation Platform
Oncology / Immunology
The Problem
Our Approach
The extracellular matrix often acts as both a physical and biochemical barrier—limiting drug penetration, modulating immune response, and reducing therapeutic efficacy.
We are exploring strategies including ECM-modulating agents to enhance drug penetration, enzyme-based approaches targeting matrix components, and ECM-informed delivery systems and combination therapies.
Why It Matters
Collaboration Opportunity
- Improves therapeutic access to target tissues
- Enhances efficacy of existing therapies
- Enables combination and immuno-modulatory strategies
We invite partners focused on tumour microenvironment modulation and combination therapy development
How We Work
Every programme is developed through a unified, execution-driven framework
We do not approach development as isolated steps—but as a connected system designed to reduce uncertainty and enable execution
Predictive Modelling
SynapTx™ — mechanistic simulation of pharmacokinetics, human exposure, and formulation behaviour
Formulation & Delivery Engineering
Advanced formulation and delivery systems engineered for stability, reproducibility, and clinical translatability
Translational & Clinical Strategy
Aligning preclinical findings with clinical objectives and regulatory expectations.
CMC Alignment & Scale-Up
Ensuring manufacturability, reproducibility, and GMP-aligned transition to clinical execution
We welcome strategic collaboration
If you are advancing a molecule with known development challenges —
exploring new delivery or activation strategies —
or seeking co-development or platform collaboration —